Kura Oncology, Inc.(KURA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,576 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in KURA
Events flagged as statistical outliers against KURA's own multi-year baseline — not fixed dollar thresholds.
KURA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Kura Oncology, Inc. (KURA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KURA at 27.6/100 on a 32-signal composite quality model, placing it at rank #2,576 of 2,962 stocks — the bottom half of the AI-ranked universe. KURA scores in the top quartile across revenue growth (86.1). Areas of concern include profitability (3.8) and balance sheet strength (4.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Kura Oncology, Inc. reports quarterly revenue of $20.9M, net income of $-68.3M, free cash flow of $-63.2M. Top institutional holders of KURA by reported 13-F value include BlackRock, SUVRETTA CAPITAL MANAGEMENT, BVF, based on the most recent SEC filings. KURA trades on the Nasdaq exchange and files with the SEC under CIK 1422143. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kura Oncology, Inc. directly from SEC EDGAR. Kura Oncology, Inc.'s 13F Pro composite quality score has ranged between 12 and 44 since 2025, currently 27.6 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$20.9M
Net Income
Q2 2026
$-68.3M
Free Cash Flow
Q2 2026
$-63.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+25.2% YoYNet Income
-60.2% YoYOperating Income
-57.2% YoYEPS (Diluted)
-57.4% YoYTotal Assets
-2.9% YoYTotal Debt
-19.9% YoYOp. Cash Flow
-147.7% YoYFree Cash Flow
-152.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $67.5M +25.2% | $53.9M | $0.00 | — | — | — |
| Net Income | $-278.7M -60.2% | $-174.0M -14.0% | $-152.6M -12.4% | $-135.8M -4.1% | $-130.5M -45.6% | $-89.6M |
| Operating Income | $-303.6M -57.2% | $-193.2M -16.5% | $-165.8M -18.5% | $-139.9M | — | — |
| EPS (Diluted) | $-3.18 -57.4% | $-2.02 +2.9% | $-2.08 -2.5% | $-2.03 -3.0% | $-1.97 -16.6% | $-1.69 |
| Total Assets | $738.4M -2.9% | $760.2M +69.3% | $448.9M -1.6% | $456.3M -14.6% | $534.1M -17.5% | $647.2M |
| Total Debt | $9.7M -19.9% | $12.1M +30.0% | $9.3M +1.9% | $9.2M | — | $7.3M |
| Operating Cash Flow | $-64.1M -147.7% | $134.3M +207.6% | $-124.8M -13.4% | $-110.1M -5.3% | $-104.6M -49.7% | $-69.8M |
| Free Cash Flow | $-70.7M -152.8% | $133.8M +207.1% | $-125.0M -12.9% | $-110.7M -4.7% | $-105.7M -46.8% | $-72.0M |
AI Insight: KURA Financial Trends
Kura is burning cash and equity at an unsustainable pace; revenue growth cannot offset operating losses.
• Revenue grew from $14M (Q1 2025) to $21M (Q2 2026), but operating losses widened from -$65M to -$73M.
• Equity collapsed 71% from $424M (Q3 2024) to $48M (Q2 2026) as net losses accumulated.
• Operating cash flow remains deeply negative; only Q4 2024 and Q4 2025 posted positive OCF ($269M, $117M).
⚠ Equity now $48M; at current burn rate (-$68M net loss in Q2 2026), runway is critically short.
⚠ Net losses accelerated from -$57M to -$81M (Q1–Q2 2025), then moderated to -$68M (Q2 2026); trajectory unclear.
AI Insight: KURA Ratio Trends
KURA is burning cash with deteriorating returns; ROE sank from -51% in Q3 2024 to -186% by Q4 2025, while leverage doubled to 0.20.
• ROA remained deeply negative, worsening from -45.5% in Q3 2024 to -46.5% in Q2 2026, signaling persistent unprofitability.
• Debt-to-equity ratio nearly doubled from 0.02 in Q3 2024 to 0.20 in Q2 2026, indicating rising financial leverage amid losses.
• ROE deteriorated sharply, declining from -51.3% in Q3 2024 to -186.1% in Q4 2025 before missing in Q1–Q2 2026.
⚠ TTM ROA of -50.5% and escalating D/E ratio suggest mounting cash burn and covenant risk if losses persist.
⚠ Absence of OpMargin and NPM data across all periods prevents visibility into unit economics and cost structure trends.
Get alerted when KURA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kura Oncology, Inc. including:
Top Institutional Holders of KURA
BlackRock, Inc.
$115.3M10,509,233 shSUVRETTA CAPITAL MANAGEMENT, LLC
$94.1M8,575,422 shBVF INC/IL
$92.7M8,445,769 shSTATE STREET CORP
$58.5M5,329,208 shVANGUARD CAPITAL MANAGEMENT LLC
$43.0M3,916,164 shARMISTICE CAPITAL, LLC
$40.3M3,678,000 shAQR CAPITAL MANAGEMENT LLC
$34.3M3,126,727 shGOLDMAN SACHS GROUP INC
$24.8M2,265,171 shGEODE CAPITAL MANAGEMENT, LLC
$24.5M2,229,958 shALETHEA CAPITAL MANAGEMENT, LLC
$23.8M2,167,938 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $115.3M | 10,509,233 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $94.1M | 8,575,422 |
| BVF INC/IL | $92.7M | 8,445,769 |
| STATE STREET CORP | $58.5M | 5,329,208 |
| VANGUARD CAPITAL MANAGEMENT LLC | $43.0M | 3,916,164 |
| ARMISTICE CAPITAL, LLC | $40.3M | 3,678,000 |
| AQR CAPITAL MANAGEMENT LLC | $34.3M | 3,126,727 |
| GOLDMAN SACHS GROUP INC | $24.8M | 2,265,171 |
| GEODE CAPITAL MANAGEMENT, LLC | $24.5M | 2,229,958 |
| ALETHEA CAPITAL MANAGEMENT, LLC | $23.8M | 2,167,938 |
Companies Similar to KURA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Syndax Pharmaceuticals Inc
Janux Therapeutics, Inc.
CYTOKINETICS INC
Invivyd, Inc.
AGIOS PHARMACEUTICALS, INC.
IOVANCE BIOTHERAPEUTICS, INC.
Crinetics Pharmaceuticals, Inc.
PRECIGEN, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KURA on your watchlist
Track score changes the day Kura Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KURA a good stock to buy?
13F Pro's AI-powered analysis of Kura Oncology, Inc. (KURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KURA are available on the KURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KURA is classified as a small company.
Which hedge funds own KURA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kura Oncology, Inc.'s investment landscape.